Table 3 Toxicities encountered during selected studies evaluating bevacizumab in advanced colorectal cancer

From: Treatment in advanced colorectal cancer: what, when and how?

Study

Treatment arms

Number of evaluable patients

Grade 3/4 hypertension (%)

Venous thrombosis (%)

Arterial thrombosis (%)

Grade 3/4 bleeding (%)

Grade 2-4 proteinuria (%)

GI perforation (%)

Kabbinavar et al (2003)

5-FU/LV

35

0

6

3

0

NR

NR

 

5-FU/LV/BEV (5 mg kg−1)

35

9

26

0

0

NR

NR

 

5-FU/LV/BEV (10 mg kg−1)

32

25

6

6

9

NR

NR

Hurwitz et al (2004)

IFL

397

2

11.4

1

2.5

6.6

0

AVF 2107

IFL/BEV

393

11

12.5

3.3

3.1

3.9

1.5

 

5-FU/LV/BEV

109

6.4

9.2

4.6

6.4

1.8a

0

Kabbinavar et al (2005b)

5-FU/LV

104

3

11

5

3

4

0

 

5-FU/LV/BEV

100

16

9

10

5

8

2

Kabbinavar et al (2005a)

5-FU/LV or IFL

237

3

9

3

2

4

0

 

5-FU/LV/BEV

244

16

10

5

5

9

1

Giantonio et al (2007)

FOLFOX

285

1.8

2.5

0.4

0.4

0

0

ECOG E3200

FOLFOX/BEV (10 mg kg−1)

287

6.2

3.4

0.9

3.4

0.7

1

 

BEV (10 mg kg−1)

234

7.3

0.4

0.4

2.1

0

1.3

Saltz et al (2007)

FOLFOX or CAPOX

675

1

5

1

1

NR

<1

XELOX-1/NO16966

FOLFOX or CAPOX/BEV

694

4

8

2

2

<1

<1

Hecht et al (2009)

FOLFOX + BEV

397

5

12

NR

NR

NR

0

PACCE

FOLFOX + BEV + panitumumab

407

4

13

NR

NR

NR

0

Hecht et al (2009)

FOLFIRI + BEV

113

2

11

NR

NR

NR

NR

PACCE

FOLFIRI + BEV + panitumumab

111

3

24

NR

NR

NR

NR

Tol et al (2009)

CAPOX + BEV

366

14.8

6.8

3.3

1.6

NR

0.3

CAIRO 2

CAPOX + BEV + cetuximab

366

9.3

8.2

2.2

0.5

NR

1.6

Berry et al (2008) BEAT

Chemotherapy + BEV

1914

5.3

NR

1.5

3.4

1.1

1.8

Grothey et al (2007) BriTE

Chemotherapy + BEV

1953

NR

NR

1.8

2.4

NR

1.8

  1. aOnly grade 3 toxicity was reported.
  2. LV=leucovorin; FOLFOX=oxaliplatin/infused 5-FU/LV; BEV=bevacizumab; CAPOX=capecitabine/oxaliplatin; IFL=irinotecan/bolus 5-FU/LV; NR=not reported.
Back to article page